US EditionResolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025 – Optimum Strategic CommunicationsLink to: Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025 – Optimum Strategic CommunicationsLink to: Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T
– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage